GENE THERAPY FOR RARE DISEASE MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027
© Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Gene Therapy for Rare Disease Market - Overview The global Gene Therapy For Rare Disease Market By Drug (Approved Drugs (Tisagenlecleucel (Kymriah), Axicabtagene ciloleucel (Yescarta), Voretigene neparvovec (Luxturna), Strimvelis), Pipeline Drugs (GT-AADC, Fidanacogene elaparvovec (SPK-9011), OTL-200, bb2121, AMT-061, and Others), By Therapeutic Application (Oncology, Neurological Disorders, Ophthalmic Disorders, Hematological Disorders, Immunodeficiency Disorders, Metabolic Disorders, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) was valued at US$ 16.3 million in 2017, and is projected to exhibit a CAGR of 35.0% over the forecast period (2018–2026). Robust pipeline, recent success of newly launched gene therapies such as Kymriah, and Yescarta, and absence of robust therapies for several rare diseases is expected to boost growth of the global gene therapy for rare disease market. Key players in the market are focused on research and development of gene therapies for rare diseases in order to introduce their pipeline products in the market. In August 2018, Kite Pharma, Inc., a Gilead Company, received European Commission (EC) Marketing approval for its novel Yescarta (axicabtagene ciloleucel), as a treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. Browse Research Reports: https://www.coherentmarketinsights.com/market-insight/genetherapy-for-rare-disease-market-2321 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Browse 26 Market Data Tables and 37 Figures spread through 240 Pages and in-depth TOC on Global Gene Therapy for Rare Disease Market By Drug (Approved Drugs (Tisagenlecleucel (Kymriah), Axicabtagene ciloleucel (Yescarta), Voretigene neparvovec (Luxturna), Strimvelis), Pipeline Drugs (GT-AADC, Fidanacogene elaparvovec (SPK-9011), OTL-200, bb2121, AMT-061, and Others), By Therapeutic Application (Oncology, Neurological Disorders, Ophthalmic Disorders, Hematological Disorders, Immunodeficiency Disorders, Metabolic Disorders, and Others), and Region (North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa) - Global Forecast to 2026 Increasing research and development by leading players in gene therapy for rare disease is expected to support growth of the gene therapy for rare disease market. Several companies have novel gene therapies in the clinical stages for treatment of rare diseases ranging from rare cancers to rare genetic diseases. For instance, Spark Therapeutics, Inc. has SPK-7001 (Choroideremia/ Phase ½), SPK-8011 (Hemophilia A/Phase ½), and SPK-3006 (Pompe Disease/preclinical) in the pipeline. Moreover, Orchard Therapeutics has multiple therapies in the pipeline such as OTL-101, OTL-103, OTL-102, OTL-200, and OTL-201 for various indications. Some of these therapies are expected to receive the U.S. Food & Drug Administration approvals during the forecast period. These factors are expected to boost the global gene therapy for rare disease market growth over the forecast period. Request a Sample copy of this reports: https://www.coherentmarketinsights.com/insight/request-sample/2321 © Coherent market Insights. All Rights Reserved
REPORT DESCRIPTION Key Takeaways of the Global Gene Therapy for Rare Disease Market: The global gene therapy for rare disease market is expected to exhibit a CAGR of 35.0% over the forecast period, owing to increasing research and development by key players in gene therapy. Price for therapies are highly dependent on prevalence of the disease and therefore, some drugs (which are in development for ultra-rare disease) may be expensive There could be a significant delay in commercialization of approved therapies in regions such as Latin America, Asia Pacific, Middle East, and Africa, as these therapies have novel technologies (as patient cells may be needed for modification and reintroduction into the patient) and high prices of gene therapy treatment.
Asia Pacific is expected to witness highest growth in gene therapy for rare disease market over the forecast period Major players operating in the global gene therapy for rare disease market include Kite Pharma, Inc. (Gilead Sciences, Inc.), Novartis International AG, Juno Therapeutics Inc. (Celgene Corporation), Bluebird Bio, Inc., Spark Therapeutics, Inc., uniQure N.V, Orchard Therapeutics Plc., PTC Therapeutics, Inc., and BioMarin Pharmaceutical Inc.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/2321 © Coherent market Insights. All Rights Reserved
ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele.
SERVICES INDUSTRY ANALYSIS
CUSTOMIZED RESEARCH
SYNDICATED RESEARCH
MARKET INTELLIGENCE SERVICES
CONSULT STUDIES
COUNTRY SPECIFIC STUDIES
© Coherent market Insights. All Rights Reserved
ABOUT CMI SECTOR COVERAGE
BIOTECHNOLOGY
CLINICAL DIAGNOSTIC
HEALTHCARE IT
MEDICAL DEVICES
MEDICAL IMAGING
PHARMACEUTICAL
OUR CLIENTS
Global Leading Equipment and System Manufacturers Marketing Consultancies and the Advertising Industry Component Providers and System Integrators
Private and Government organization
Distributors, Retailors and Value Added Resellers
Outsourcing Companies
Healthcare IT Solutions Developers
Universities and Business Schools.
© Coherent market Insights. All Rights Reserved
KEY STATS
RESEARCH SOLUTIONS
100+
FEASIBILITY STUDIES
Insights Published Per Year
GLOBAL REPORTS
150+
Consulting Projects Till Date
COUNTRY ANALYSIS CONSULT PROJECTS
125+
Clients Worldwide Per Year
110+
SURVEY RESEARCH
EXCEL FORECAST DATABASE
CUSTOMIZED SOLUTIONS
COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS
Analysts and Contract Consultants
Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved
THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702
© Coherent market Insights. All Rights Reserved